Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 07:00 ET | Source: Abpro Corporation

Abpro Announces 1-for-30 Reverse Stock Split Effective November 3, 2025

Achieved ~60% reduction in operating costs through a focused cost optimization plan DiversImmune® platform positioned to unlock additional pipeline value Reverse stock split supports Nasdaq...
September 01, 2025 03:05 ET | Source: Boehringer Ingelheim Limited

Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1...
August 08, 2025 15:25 ET | Source: Boehringer Ingelheim Limited

U.S. FDA grants accelerated approval to Boehringer’s HERNEXEOS® as first orally administered targeted therapy for previously treated patients with HER2-mutant advanced NSCLC

This press release is not intended for UK media. HERNEXEOS® (zongertinib tablets) approved based on an objective response rate of 75% (N=71), as demonstrated in the Beamion-LUNG 1 clinical...
April 27, 2025 14:00 ET | Source: Abpro Corporation

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager

Abpro and Celltrion Unveil Preclinical Data for ABP-102/CT-P72 at AACR 2025, Showcasing Potential Best-in-Class HER2 x CD3 T-Cell Engager
March 25, 2025 16:30 ET | Source: Abpro Corporation

Abpro Announces Oral Presentation of First Preclinical Data for ABP-102/CT-P72, a Tetravalent Bispecific HER2 x CD3 T-Cell Engager, at AACR Annual Meeting 2025

WOBURN, Mass., March 25, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and...
September 09, 2024 20:30 ET | Source: Transparency Market Research

Companion Diagnostic Tests in Oncology Market Size is Set to Achieve USD 17.0 Billion by 2034, with 9.5% CAGR: Transparency Market Research Inc.

Wilmington, Delaware, United States, Transparency Market Research, Inc. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- The global companion diagnostic tests in oncology market (الاختبارات التشخيصية المصاحبة...
September 09, 2024 11:45 ET | Source: Boehringer Ingelheim

Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients

Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1Preliminary activity in...
May 20, 2024 12:30 ET | Source: Custom Market Insights

[Latest] Global Colorectal Cancer Market Size/Share Worth USD 30,095.9 Million by 2033 at a 3.4% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, May 20, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Colorectal Cancer Market Size, Trends and Insights By Type of Treatment (Surgery,...
May 06, 2024 08:30 ET | Source: Custom Market Insights

[Latest] Global Breast Cancer Therapeutics Market Size/Share Worth USD 66.1 Billion by 2033 at a 6.8% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)

Austin, TX, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Breast Cancer Therapeutics Market Size, Trends and Insights By Type of Therapy...
November 10, 2021 14:22 ET | Source: The Rosen Law Firm PA

SBTX SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Silverback Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SBTX

NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...